---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-008543"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2026-08-10T21:15:17+00:00"
generated_at: "2026-08-10T21:16:28.919602+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeOnc reports Q2 2026 net loss of $14.2M; confirms Aug 12 Phase 2a NEO100 topline data

## Summary
- Net loss $14.2M ($0.58/sh) vs $5.7M ($0.30/sh) in Q2 2025; R&D up to $2.6M from $0.7M.
- Cash $2.0M at 6/30/26; undrawn $10M HCWG credit line; $44.5M available under Mast Hill facility.
- Received UAE IND approvals for NEO100 (covering all programs) and NEO212 (Phase 2) in June 2026.
- FDA written feedback on NEO212 CMC and tablet formulation received July 2026; official minutes expected Aug 2026.
- Phase 2a NEO100 topline results to be presented Aug 12, 2026; Nasim Shomali appointed to board effective July 1, 2026.

## SEC filing metadata
- accession: 0001829126-26-008543
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2026-08-10T21:15:17+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912626008543/0001829126-26-008543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912626008543/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-008543
- JSON: https://secwatch.observer/filing/0001829126-26-008543.json
- Plain text: https://secwatch.observer/filing/0001829126-26-008543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.